 |
 |
|
|
|
WELCOME TO THE CARDIOVASCULAR JOURNAL OF AFRICA |
 |
The Cardiovascular Journal of Africa (CVJA) is
an international peer-review journal that keeps cardiologists up
to date with advances in the diagnosis and treatment of cardiovascular
disease.
Topics covered include coronary disease, electrophysiology,
valve disease, imaging techniques, congenital heart disease (fetal,
paediatric & adult), heart failure, surgery, & basic science.
CVJA is the official journal of the PASCAR and has been
published since 1990. |
| |
CVJA Readership
Increased by 33% - Pubmed Statistics
The most recent report on the link-out facility to full text
articles published in the CVJA shows a 30% increase in
readership in January this year.
Read More »
Latest News
Dabigatran approved in UK NHS for
stroke prevention in atrial fibrillation
Importance of assessment of renal function in dabigatran
treatment re-affirmed. The NICE guideline committee has
approved the use of dabigatran etexilate
for prevention of stroke and systemic
embolism in patients with atrial fibrillation
(AF), based on the RE-LY studies
and additional cost-effectiveness data. It
has included this recommendation in its
final appraisal determination.
Read More »
Dramatic reductions in plaque volumes on maximum statin therapy:
Largest IVUS trial shows equal plaque regression with
atorvastatin and rosuvastatin
The SATURN trial, which evaluated the extent of plaque
regression in patients with symptomatic coronary artery disease
(CAD) over a two-year period using maximum doses of atorvastatin
and rosuvastatin, showed no difference between these two statins
with regard to the primary endpoint of percentage reduction of
atheroma volume.
Read More »
Raft of Rivaroxaban: good news from the USA, implications for
SA clinical practice
Rivaroxaban has been approved by the US Food and Drug
Administration (FDA) for the prevention of stroke and systemic
embolism in non-valvular atrial fibrillation.
From the American
Heart Association (AHA) 2011 congress earlier this week, the
results of the ATLAS ACS 2-TIMI 51 trial have shown rivaroxiban
improves cardiovascular outcomes and reduces cardiovascular and
all-cause mortality in acute coronary syndromes (ACS).
Read
more »
|
| |
 |
How to write a scientific paper
- Free Download!!
|
|
| |
|
Latest Cardiovascular Journal of Africa Vol
22, Issue 6
- Asymptomatic left ventricular systolic dysfunction in
hypertensive Nigerians
- Metabolic syndrome in Asian Indians
- Down syndrome and congenital heart disease
- Diagnosis and follow up of primary cardiac tumours
- Stromal-derived factor-1<alpha>/CXCR4 in
neo-intimal repair
- Omega-3 fatty acid content of fish oil supplements
- Increasing rates of hypertension in women
- Anaesthesia for emergency Caesarean section in
peripartum cardiomypathy
- 3D transoesophageal echocardiography in prosthetic
mitral valve thrombosis
- Read Full Text »
|
| |
|
News for Authors: |
| |
|
The CVJA Online First Advanced Publication
latest articles:
|
| |